Doç. Dr. Yaşa Gül Mutlu

Berufserfahrung

• 2019-2020Muş Devlet Hastanesiİç Hastalıkları Uzmanı
• 2014-2015Çanakkale Devlet HastanesiPratisyen Hekim

Ausbildung

• 2020-2024İstanbul Medipol Üniversitesi, Hematoloji Yan Dal Uzmanlık Eğitimiflorence.com.tr
• 2017-2019Dokuz Eylül Üniversitesi Tıp Fakültesi, İç Hastalıkları Uzmanlık Eğitimiflorence.com.tr
• 2015-2017Çukurova Üniversitesi Tıp Fakültesi, İç Hastalıkları Uzmanlık Eğitimiflorence.com.tr
• 2008-2014Mustafa Kemal Üniversitesi Tıp Fakültesi, Tıp Eğitimiflorence.com.tr

• FachgebietHämatologieflorence.com.trAus der Quelle
• Einrichtungİstanbul Florence Nightingale Hastanesiflorence.com.trAus der Quelle
• Publikationen21 PublikationenProfilseite auf florence.com.trAus der Quelle
• Letzte Synchronisierung7. November 2026 07:30https://www.florence.com.tr/doktorlar/uzm-dr-yasa-gul-mutluflorence.com.tr

1. Balik Aydin B, Mutlu YG, Sevindik OG. Persistent Polyclonal B-Cell Lymphocytosis with Binucleated Lymphocytes. Turk J Haematol. 2021;38(2):173-4.

   Quelle: Profilseite auf florence.com.tr

2. Civriz Bozdag S, Cengiz Seval G, Yonal Hindilerden I, Hindilerden F, Andic N, Baydar M, …. Mutlu YG ,…et al. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. Turk J Haematol. 2022;39(1):43- 54.

   Quelle: Profilseite auf florence.com.tr

3. Sevindik OG, Mergen M, Mergen S, Mutlu YG, Aydin BB, Serin I. To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission. Ann Hematol. 2022;101(11):2545-7.

   Quelle: Profilseite auf florence.com.tr

4. Sevindik OG, Mutlu YG, Aydin BB, Serin I. First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS). Hemasphere. 2022;6(7):e728.

   Quelle: Profilseite auf florence.com.tr

5. Yigit Kaya S, Bektas S, Askin AE, Balik Aydin B, Mutlu YG, Sevindik OG. Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient. Ann Hematol. 2023;102(6):1599-600.

   Quelle: Profilseite auf florence.com.tr

6. Mutlu YG, Aydin BB, Erdogan C, Kizilaslan D, Bekoz HS, Gemici A, et al. Prognostic Factors and Intensive Care Outcome in Post-Transplant Phase of Hematopoietic Stem Cell Transplantation: Intensive Care Outcome in Hematopoietic Stem Cell Transplantation. Indian J Hematol Blood Transfus. 2023;39(2):167-72.

   Quelle: Profilseite auf florence.com.tr

7. Mutlu YG, Balik Aydin B, Ayaz A, Seca F, Sevindik OG. Mutation profile of the patients diagnosed with myeloid neoplasia tested with next generation sequencing andclinical implications. Annals of Medical Research. 2022; 29(4), 406-411.

   Quelle: Profilseite auf florence.com.tr

8. Sadri S. , Yönal Hindilerden İ. , Mutlu YG. , Tiryaki T. O. , Gemici A. İ. , Bekoz H. S. , Gökmen Sevindik Ö. , Hindilerden F. , Kalayoğlu beşışık S. , Nalçacı M. , Sargın D. Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers. Eur Res J. 2023; 1-12.

   Quelle: Profilseite auf florence.com.tr

9. Mutlu YG, Aydin BB, Cakir A, Canoz O, Erol C, Sevindik OG.Should core needle lymph node biopsy be a relevant alternative to surgical excisional biopsy in diagnostic work up of lymphomas? 2023, Eurasian J Med.

   Quelle: Profilseite auf florence.com.tr

10. Erol VB, Mutlu YG, Aydin BB, Mert A, Sevindik OG. Intravascular B cell lymphoma with generalized telangiectasias: a rare entity. 2023, J Dtsch Dermatol Ges.

    Quelle: Profilseite auf florence.com.tr